Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update outlining significant pipeline expansion and clinical milestones. The company announced plans to acquire worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics targeting EGFR-mutated lung cancer and other cancers. CL-741 is designed to complement Kairos Pharma's existing portfolio, which includes ENV-105, KROS-201, KROS-102, and ENV-205.
Kairos Pharma expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations. The company also reported securing more than $8 million in non-dilutive funding to support the development of its preclinical and clinical programs.
ENV-105, the company's lead candidate, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. It is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. As of the date of the press release, ENV-105 has not been approved as safe or effective by the U.S. Food and Drug Administration or any other comparable foreign regulator.
The acquisition of CL-741 represents a strategic expansion into the oral kinase inhibitor space, potentially addressing significant unmet needs in EGFR-mutated lung cancer. The company's focus on overcoming drug resistance and immune suppression in cancer aligns with its use of structural biology to develop novel therapeutics.
Kairos Pharma, based in Los Angeles, California, continues to advance its pipeline while leveraging non-dilutive funding to minimize shareholder dilution. The company's mid-year update provides a clear roadmap for the remainder of 2026, with key data readouts and trial initiations anticipated.
For more information, visit the company's newsroom at https://ibn.fm/KAPA and view the full press release at https://ibn.fm/WuBOf.
